





Understanding Cancer Lecture 6 **Types of signalling** pathway: normal and dysregulated GPCR

DR HAFSA WASEELA ABBAS www.hafsaabbas.com



RECAP:

What you hopefully should understand so far from Lecture 5



- The first messenger in the cell-signalling pathway is the ligand. The secondary messenger helps transduce the signal to elicit a response.
- Calcium ion channels are found in the mitochondria, endoplasmic reticulum and plasma membrane. It is regulated to maintain its low concentration in cells. It binds specifically to the calcium-binding protein Calmodulin.



cAMP plays a key role in signal transduction pathway. It is activated by adenyl cyclase where it then binds to protein kinase A to activate more proteins in the signal cascade. cAMP is deactivated by phosphodiesterase.



Diacylglerol (DAG) and Inositol triphosphate (IP_3) are secondary messengers that are involved in the phosphorylation of downstream targets and stimulate other secondary messengers e.g. calcium ions respectively.

Transcription factors regulate the expression of genes which affects cellular response.

What will we learn today?

- The structure of the G-protein coupled receptor (GPCR)
 - The subtypes of GPCR



- Normal GPCR signalling pathway: Cellular response
- Turning off GPCR signalling pathway
- Causes of dysregulated GPCR signalling pathway
- Examples of cancers caused by dysregulated GPCR signalling pathway

GENTLE REMINDER An ideal way of learning:

Monday Tuesday Wednesday Thursday Friday Saturday Sunday

Mini-lectures.

Approximate total time: 1 hour Divide over 7 days at your <u>own pace</u>. Challenge yourself with a quiz!



www.hafsaabbas.com

RECAP: How to support your learning?



Glossary to help understand what key words mean.



Summary doodle revision posters by HN designs.



Quizzes to test your knowledge and reflect.



Reference list for further reading.

Acknowledgements: Special thanks to my parents, family, friends and colleagues for their support and the respected teachers and health professions who taught me and installed the passion of cancer/oncology.

The structure of the G-protein coupled receptor (GPCR)

The structure of the G-protein coupled receptor (GPCR)

GPCRs are helical transmembrane receptor proteins found on the cell surface.

GPCR genes account for 5% of the human genome.

The **cell surface receptor** is divided into three regions:

Extracellular loop region (ECR)	This is where binding to specific ligand occurs
	There are seven transmembrane proteins in the cell surface receptor.
Transmembrane region (TM)	The shape of these proteins is helical and play an important role in how the intracellular and extracellular environments communicate. The conformational changes occurs here
Intracellular membrane loop (ICR)	It is where the signal transduction pathway occurs by interacting with intracellular proteins called G proteins.





The subtypes of GPCR

The subtypes of GPCR

Most GPCRs contain **seven helices** and **three intracellular loops.**

Some members of the **rhodopsin family** may have **eight helices and four intracellular loops.**





Normal GPCR signalling pathway: Receptor activation

Normal GPCR signalling pathway: Receptor activation

1.The ligand binds to GPCR and this binding causes a conformational change.

Common ligands are: amino acids, hormones, neurotransmitters, chemokines, proteins and small ions.

2. This leads to interaction with intracellular proteins called G proteins.



The structure of G-proteins

The G proteins consist of three subunits (Gα, Gβ and Gγ) and is known as a heterotrimer.



The structure of G-proteins

G proteins are classified according to their a subunit; Gai, Gas, Ga12/13, and Gaq.

Gαi and Gαs

 They regulate adenylyl cyclase activity.





Gαs activates adenyl cyclase activity.

• Gαi halts adenyl cyclase activity





Phosphatidylinositol (PI) phospholipid is phosphorylated by kinase enzymes to form PI-phosphate (PIP) and PI-bisphosphate (PIP₂).

The G α q/11 activates the enzyme phospholipase c (PLC)who then cleaves PIP₂.

PLC cleaves PIP₂ to form two second messengers: Diacylglerol (DAG) and Inositol triphosphate (IP₃)

GTPase binding domain

Helical domain

The exchange of bound GDP for guanosine triphosphate (GTP). It has three switch regions

that are flexible loops that change conformation when bound with GTP.

It also binds the Gβγ subunits and GPCR.

Six alpha helices that has nucleotides in the protein core.

Normal GPCR signalling pathway: Receptor activation

3. The activated receptor activates G protein and exchanges for guanosine-5'diphosphate (GDP) for guanosine-5'-triphosphate (GTP).

4. Levels of the ligand decreases.



Phosphate Phosphate Sugar Guanosine diphosphate (GDP)

Active state

GTPase activity promotes the exchange of bound GDP for guanosine triphosphate (GTP).

Inactive state

The $\boldsymbol{\alpha}$ subunit bound to

guanosine diphosphate (GDP).



Normal GPCR signalling pathway: Signal transduction

Normal GPCR signalling pathway: Signal transduction

5. Alpha subunit of the G protein binds to the enzyme adenyl cyclase on the plasma membrane.

6. The α subunit and $\beta\gamma$ complex then dissociate from one another



Normal GPCR signalling pathway: Signal transduction 7. The activation of adenyl cyclase stimulates the production of the intracellular second messenger cyclic

adenosine monophosphate (cAMP) from

adenosine triphosphate (ATP).





The concentration of intracellular cAMP depends on the relative balance between adenylyl cyclases and phosphodiesterases

(PDE).



22 PDEs have been identified.

Types of cAMP targets: Epac

It is a guanosine exchange factor (GEF). The structure of Epac has a cAMP binding domain. This causes a conformational changes of the protein. This exposes the active site in the catalytic domain.

Source: Creative Commons, 2023



Types of cAMP targets: cyclic nucleotide-gated ion channels

They cation channels that can conduct calcium, sodium and potassium ions and change the cell membrane potential.

Cyclic nucleotide-gated (CNG) channels.

Hyperpolarization-activated cyclic nucleotide-modulated (HCN) channels.





PKA

Types of cAMP targets: PKA Activated receptor It is a tetramer enzyme and can be classifled into: PKA type I (RIα2C2, RIβ2C2) -**A**) cytoplasm Protein **cAMP** kinase A B) PKA type II (RIIα2C2, RIIβ2C2) subcellular structures and

compartments

cAMP binds to the enzyme cAMP-dependent kinase (A-kinase)

Protein

kinase A

cAMP

Plasma

membrane

Types of cAMP targets: PKA

PKA is made of **four subunits**:

- Two catalytic subunits
- Two regulatory subunits.

In mammals:

There are four types of regulatory subunits: $RI\alpha$, $RI\beta$, $RII\alpha$ and $RII\beta$.

There are three types of catalytic subunits: $C\alpha$, $C\beta$ and $C\gamma$.







Types of cAMP targets: PKA

Catalytic subunit

Regulatory subunits

• They are bound to each other and initiate catalytic subunits.

Normal GPCR signalling pathway: Signal transduction

8. The regulatory subunits are bound to each other and initiate catalytic subunits.


Normal GPCR signalling pathway: Signal transduction

9. cAMP binds to the regulatory subunits of PKA.

This activates both catalytic subunits of PKA by separating the regulatory and catalytic subunits.





Normal GPCR signalling pathway: Signal transduction

10. The activated catalytic subunits of PKA phosphorylate specific cellular proteins in the serine and threonine residues.



Did you know?

Recent study 1

PKA is an actomyosin contractility-regulated effector involved in cell migration.

Recent study 2

PKA phosphorylates CDC42 interacting protein 4 (CIP4).

It facilitates membrane deformation and actin polymerization.

It promotes cancer cell invasion and metastasis.

<u>Recent study 3</u>

Activated PKA can inhibit adenylyl cyclase (AC5 and AC6) and activate phosphodiesterase (PDE3 and PDE4). This lowers the levels of cAMP.

Did you know?

PKA anchored proteins

(AKAPs)

It can bind to cytoskeleton proteins or organelles and to PKA regulatory subunits.



Examples of PKA targets: CREB

It is a member of **basic leucine zipper (bZIP) superfamily transcription factors:**

□ cAMP response element-binding protein (CREB) – many tissues.

□ cAMP responsive element regulatory protein (CREM) – many tissues.

□ Transcriptional activator 1 (ATF1) - neuroendocrine

They can form homodimers or heterodimers.

They all have a **KID (kinase inducible domain)** is a 60-amino acid fragment located in the **central region and contains the PKA phosphorylation site (RRPSY).**

This is for cyclins, apoptotic proteins, growth factors, enzymes and transcription factors.

Examples of PKA targets: CREB



Structure of CREB

- □ kinase inducible domain (KID)
- □ Two glutamate domains (Q1 and Q2)
- □ A basic leucine zipper domain (bZIP)

CREB pathway

CREB/ATF1 can be phosphorylated by multiple kinases including Akt, RSK, MSK, PKA, CAMKII and CAMKIV. Phosphorylation of CREB Ser133 residue and ATF1

Ser63 residue takes place.



Activated ATF1 and CREB can form homodimer or heterodimer and bind to the cAMP response element (CRE) in the promoter region of target genes.

Regulate transcription of target genes to initiate cellular response e.g. oncogenes c-Jun and cyclin D1.

G-protein independent pathway

Bicarbonate (HCO₃⁻) and calcium ions (Ca²⁺) induce cAMP synthesis by activating the soluble adenylyl cyclase (sAC) without G-proteins.

Cellular response



11. The ligand dissociates from receptor which inactivates GPCR.

12. The ligand degrades.

13. The alpha subunit of the intracellular Gprotein hydrolyses GTP to GDP+P.

14. The alpha subunit and beta/gamma dimer reassociate to an inactive G protein. 15. The levels of cAMP decrease because the enzyme called phosphodiesterase converts cAMP to AMP. 16. The low levels of cAMP cause the regulatory subunits of PKA to release cAMP.

16. The regulatory and catalytic subunits of PKA reassociate and is stimulated by protein phosphatases. This prevents the actions of PKA. GPCR signaling pathway is involved in cancer growth and development and partakes in a number of hallmarks of cancer:

- Unregulated growth
- □ Invasion
- Metastasis
- Evading apoptosis
- **Evading immune response**
- □ Angiogenesis.

Causes of dysregulated GPCR signalling pathway



What is a point mutation?

SILENT MUTATION	MISSENSE	NONSENSE	SPLICE-SITE
		A change the codon	
	The DNA sequence has	(substitution of base	It offorto.
	been changed because	pair) from an amino	
lt changes DNA	there was a substitution.	acid to create a stop	the exons (coding regions)
sequence but has		codon.	and introns (non-coding
no effect on the	This causes a different		regions) where some
amino acid and	amino acid to be made.	This causes a short	introns are added and
protein.		protein to form that	some exons are removed.
	This affects the shape and	are either non-function	
	function of the protein.	or functional but is	lt prevents splicing and
		affected.	form a different protein



Source: Creative Commons, 2023

Causes of dysregulated GPCR signalling pathway

Activation of alpha subunit of G proteins via these molecules:

□ Chemokines e.g. Interleukin 8 (IL8)

□ Neuropeptides e.g., prostaglandin E2

Lipids e.g., lysophosphatidic acid (LPA)

This leads to activation of targets to increase:

Migration

Proliferation

Survival of tumour cells by increasing nutrient supply via angiogenesis.

Regulating the degradation of the extracellular matrix.

A number of biomarkers can be established to diagnose cancer early and develop cancer preventative treatments.

cAMP–PKA signaling

TUMOUR-SUPPRESSIVE

TUMOUR-PROMOTING





It phosphorylate and then inactivate the calmodulindependent protein kinase kinase-2 (CAMKK2). CaMKK2 plays roles in energy homeostasis, insulin signalling.

Examples of cancers caused by dysregulated GPCR signalling pathway

Examples of cancers caused by dysregulated GPCR signalling pathway

Endocrine	Thyroid (anaplastic)	Ovary	Gastrointestinal
Prostate	Bladder	glioblastoma (GBM)	atypical fibroxanthoma (AFX)
Colorectal	chronic lymphoblastic leukaemia (CLL)	pleomorphic dermal sarcoma (PDS)	Hepatocellular carcinoma (HCC)

Hepatocellular Carcinoma (HCC)



Hepatocellular Carcinoma (HCC)

Inhibition of CAMKK2 protects against HCC induced by a high-fat diet. Fibrolamellar hepatocellular carcinoma (FL-HCC) is a primary liver cancer that occurs mainly in children and young adults.
80%-100% FL-HCC patients have DNAJB1–PRKACA gene fusion. This results in: *A)* Deleting a 400 kb gene fragment on chromosome 19 *B)* The production of a chimeric protein that

retains PKA kinase activity.

Hepatitis B virus (HBV) infection increases risk of HCC.

HBV X protein can promote liver carcinogenesis through CREB-miR-3188 and ZHX2-Notch signaling pathways. This increases cancer cell growth and invasion.

Brain cancer

<u>Glioblastoma</u>

Activation of PKA: Increases cAMP levels. Upregulates the expression of p21 and p27. This increases proliferation, differentiation, and apoptosis.

Medulloblastoma

Pituitary adenylyl cyclase inhibits proliferation via the PKA-Gli1 pathway.





Medulloblastoma

Tumor

(Netmeds.com, 2021)

Lung cancer

<u>Non-small cell lung cancer</u> <u>(NSCLC)</u> Increased CREB expression

and phosphorylation in tumour tissues.

This lowers patient survival. cAMP can lower apoptosis. Small cell lung cancer (SCLC) Increased CREB expression induces proliferation. CAMP–PKA–CREB pathway could regulate the hypoxia response in lung cancer cells. PKA increases cell migration and invasion. PKA induces Protein phosphatase 2 (PP2A)

phosphorylation and AP1.

This increases apoptosis.

Lung cancer



Prostate cancer

Inhibition of CAMKK2 protects against prostate cancer.

Progression of prostate cancer through PKA kinase

PKA subunit can be a biomarker to predict the response of to radiotherapy and chemotherapy.

PKA RIα overexpression is associated with poorefficacy of radiotherapy and metastasis.

Testosterone stimulates GPR56 directly and activates the cAMP/PKA pathway. This induces Androgen receptor (AR) signalling required for prostate carcinogenesis.



Ovarian cancer

PKA RIα is highly expressed in epithelial ovarian cancer It promotes invasion and metastasis by phosphorylating claudin-3 protein which lowers the intensity of tight junctions and degrades the extracellular matrix. Low CREB expression decreases proliferation but has no effect on

apoptosis.

Ovarian Cancer



Colorectal cancer

PKA RIα and AKAP10 increased tumour progression and metastasis lowering survival.

Type-I insulin-like growth factor receptor (IGF-IR) signaling stimulates the phosphorylation of ezrin protein.

This leads to cAMP-PKA signalling and increase tumour survival.



Breast cancer

PKA increases the growth and metastasis of triple negative breast cancer cells through GSK3-βcatenin pathway.

PKA induces chemotherapy resistance e.g. trastuzumab resistance in Her-2 positive breast cancer.

PKA RI subunit increases proliferation in normal cells and breast cancer metastasis

G-protein coupled estrogen receptor increases aerobic glycolysis through cAMP–PKA–CREB pathway.



© 2017 medicalartlibrary.com

Metastatic breast cancer

Blood cancers

Leukaemia

Overexpression of CREB is found in the bone marrow of most leukemia cell lines

B cell chronic lymphocytic leukemia (CLL)

PDE4 inhibitors induces apoptosis by increasing cAMP levels and blocking Toll-like receptor (TLR) signalling.

(TLRs) have a major role in innate immune responses.

Chemokines CXCR4 and CXCL12 released from the microenvironment can bind to Gαiconjugated GPCRs on CLL cells. This lowers cAMP synthesis and increasing tumour survival.

WHAT IS Leukemia?

A cancer found in the blood and bone marrow, caused by too many white blood cells in the body. The white blood cells don't let the body fight disease and prevent the body from making red blood cells and platelets.



Normal White Blood Cell Count



Abnormal White Blood Cell Count

4 TYPES OF LEUKEMIA

Acute Lymphoblastic Leukemia



- Found in lymphoid cells
- Grows quickly
- Common in children
- 6,000 cases a year

Found in

Acute

Myelogenous

Leukemia

- myeloid cellsGrows quickly
- Common in adults
 and children
- 18,000 cases a year

Chronic Lymphoblastic Leukemia



- Found in lymphoid cells
 Grows slowly
- Common in adults 55+
- 15,000 cases
- a year

Chronic Myelogenous Leukemia



- Found in myeloid cells
- Grows slowly
- Common in adults
- 6,000 cases a year


Blood cancers

Lymphoma

cAMP–PKA increases expression of Bax and lowers expression of anti-apoptotic proteins BcI-2 and survivin. This increases the rate of apoptosis.

LYMPHOMA signs and symptoms



Vector Stock®

By the end of this lecture, you should understand

- GPCRs are helical transmembrane receptor proteins found on the cell surface. It has three domains made of loops: Extracellular, Transmembrane and Intracellular
- The activated receptor activates G protein and exchanges for guanosine-5'-diphosphate (GDP) for guanosine-5'-triphosphate (GTP).
- G proteins are classified according to their a subunit; Gai, Gas, Ga12/13, and Gaq.
- Adenyl cyclase stimulates the production of the intracellular second messenger cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP).
- CAMP stimulates the protein kinase A made of two catalytic subunits and two regulatory subunits. cAMP binds to the regulatory subunits of PKA.
- cAMP response element-binding protein (CREB) is a transcription factor and one of PKA targets that regulate transcription of target genes to initiate cellular response..
- Dysregulated GPCR signalling is caused by point mutations. cAMP- PKA-CREB signalling has tumour suppressive and tumour promoting roles. Increase in PKA and cAMP levels increases proliferation, differentiation, cell migration and invasion and apoptosis.

Reference list for further reading

Abe, Y. and Tanaka, N. (2016) 'The hedgehog signaling networks in lung cancer: The mechanisms and roles in tumor progression and implications for cancer therapy', BioMed Research International, 2016, pp. 1–11. doi:10.1155/2016/7969286.

Arakaki, A., Pan, W.-A. and Trejo, J. (2018) 'GPCRs in cancer: Protease-activated receptors, endocytic adaptors and signaling', International Journal of Molecular Sciences, 19(7), p. 1886. doi:10.3390/ijms19071886.

Bar-Shavit, R. Maoz, M., Kancharla, A., Nag, J., Agranovich, D., Grisaru-Granovsky, S. and Uziely, B (2016) 'G protein-coupled receptors in cancer', International Journal of Molecular Sciences, 17(8), p. 1320. Craven, K.B. and Zagotta, W.N. (2006) 'CNG and HCN channels: Two peas, One pod', Annual Review of Physiology, 68(1), pp. 375–401.

Dorsam, R.T. and Gutkind, J.S. (2007) 'G-protein-coupled receptors and cancer', Nature Reviews Cancer, 7(2), pp. 79–94.

Reference list for further reading

Gupta, M., (2017) "G protein-coupled receptors" Available [online]

https://www.slideshare.net/MeenakshiGupta57/g-proteincoupled-receptors

Istockphoto (2023) "Colorectal cancer issue stock illustration." Available [online]

https://www.istockphoto.com/vector/colorectal-cancer-issue-gm1161291250-318158081

Kamato, D., Thach, L., Bernard, R., Chan, V., Zheng, W., Kaur, H., Brimble, M., Osman, N. and Little, P.

(2015) "Structure, function, pharmacology, and therapeutic potential of the G protein, $G\alpha/q$,11" Frontiers in Cardiovascular Medicine 2 (14).

Khera, G. (2017) "Glioblastoma: The Cancer of Brain" Available [online]

https://www.scientificanimations.com/glioblastoma-cancer-brain/

Luo, J. and Yu, F.-X. (2019) 'GPCR-Hippo Signaling in Cancer', Cells, 8(5), p. 426. doi:10.3390/cells8050426. Medical Art Library (2023) "Breast Cancer" Available [online] https://medicalartlibrary.com/breast-cancer/ Netmeds.com (2021) "Medulloblastoma: Causes, Symptoms And Treatment" Available [online] https://www.netmeds.com/health-library/post/medulloblastoma-causes-symptoms-and-treatment

Reference list for further reading

Nisar, S., Hashem, S., Macha, MA., Yadav, SK., Muralitharan, S., Therachiyil, L.,Sageena, G.,Al-Naemi, H., Haris, M. and Bhat, AA. (2020) 'Exploring dysregulated signaling pathways in cancer', Current Pharmaceutical Design, 26(4), pp. 429–445.

Wang, H., Xu, J., Lazarovici, P., Quirion, R. and Zheng, W. (2018) "cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia" Frontiers in Molecular Neuroscience 11

Zhang, H., Kong, Q., Wang, J., Jiang, Y and Hua, H. (2020) 'Complex roles of camp–PKA–Creb signaling in cancer', Experimental Hematology & amp; Oncology, 9(1). 9:32







Understanding Cancer Lecture 7 **Types of signalling** pathway: normal and dysregulated EGFR

DR HAFSA WASEELA ABBAS www.hafsaabbas.com

